Business Description
Cynata Therapeutics is an Australian biotechnology company focused on developing stem cell-based treatments for serious medical conditions. Its proprietary Cymerus platform uses induced pluripotent stem cell technology to produce therapies targeting conditions such as graft versus host disease, osteoarthritis, diabetic foot wounds, and kidney transplant complications. The company has multiple products at various stages of clinical trials and operates under a licensing agreement with Fujifilm Corporation. Founded in 2003 and headquartered in Cremorne, Australia, Cynata has grown from its origins as Eco Quest Limited into a clinical-stage therapeutics business.
